These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 16312132

  • 1. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
    Gonzalez-Rey E, Delgado M.
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.
    Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J.
    J Mol Med (Berl); 2002 Jan; 80(1):16-24. PubMed ID: 11862320
    [Abstract] [Full Text] [Related]

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D, Rodriguez R, Delgado M.
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
    [Abstract] [Full Text] [Related]

  • 4. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M, Reduta A, Sharma V, Ganea D.
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M, Jonakait GM, Ganea D.
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
    Gonzalez-Rey E, Delgado M.
    Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
    [Abstract] [Full Text] [Related]

  • 7. Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation.
    Chorny A, Gonzalez-Rey E, Delgado M.
    Ann N Y Acad Sci; 2006 Nov; 1088():187-94. PubMed ID: 17192565
    [Abstract] [Full Text] [Related]

  • 8. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
    Delgado M, Gonzalez-Rey E, Ganea D.
    FASEB J; 2004 Sep; 18(12):1453-5. PubMed ID: 15231725
    [Abstract] [Full Text] [Related]

  • 9. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
    Gonzalez-Rey E, Varela N, Chorny A, Delgado M.
    Curr Pharm Des; 2007 Sep; 13(11):1113-39. PubMed ID: 17430175
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions.
    Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M.
    Regul Pept; 2006 Nov 15; 137(1-2):67-74. PubMed ID: 16949684
    [Abstract] [Full Text] [Related]

  • 12. VIP-PACAP system in immunity: new insights for multitarget therapy.
    Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C.
    Ann N Y Acad Sci; 2006 Jul 15; 1070():51-74. PubMed ID: 16888149
    [Abstract] [Full Text] [Related]

  • 13. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.
    Leceta J, Gomariz RP, Martinez C, Carrión M, Arranz A, Juarranz Y.
    Neuroimmunomodulation; 2007 Jul 15; 14(3-4):134-8. PubMed ID: 18073504
    [Abstract] [Full Text] [Related]

  • 14. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D, Delgado M.
    Arch Immunol Ther Exp (Warsz); 2001 Jul 15; 49(2):101-10. PubMed ID: 11348014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4.
    Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martínez C.
    Peptides; 2008 Jun 15; 29(6):948-56. PubMed ID: 18359536
    [Abstract] [Full Text] [Related]

  • 18. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.
    Gutiérrez-Cañas I, Juarranz Y, Santiago B, Martínez C, Gomariz RP, Pablos JL, Leceta J.
    Brain Behav Immun; 2008 Mar 15; 22(3):312-7. PubMed ID: 17951026
    [Abstract] [Full Text] [Related]

  • 19. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?
    Pozo D, Delgado M.
    FASEB J; 2004 Sep 15; 18(12):1325-34. PubMed ID: 15333575
    [Abstract] [Full Text] [Related]

  • 20. Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells.
    Gonzalez-Rey E, Delgado M.
    Brain Behav Immun; 2008 Jan 15; 22(1):35-41. PubMed ID: 17826030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.